Specialty life sciences company Revive Therapeutics has signed a research agreement with University of California, San Francisco (UCSF) to study Bucillamine as a potential treatment for severe Covid-19.
The post Revive Therapeutics, UCSF partner to study Bucillamine for severe Covid-19 appeared ...

https://www.pharmaceutical-business-review.com/news/revive-ucsf-bucillamine-severe-covid-19/

#PharmaceuticalBusinessReview

ViiV Healthcare has initiated a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for long-acting cabotegravir to prevent human immunodeficiency
The post ViiV begins rolling submission for cabotegravir to prevent HIV in US appeared first on ...

https://www.pharmaceutical-business-review.com/news/viiv-rolling-submission-cabotegravir-prevent-hiv/

#PharmaceuticalBusinessReview

The US Food and Drug Administration (FDA) has expanded the emergency use authorisation (EUA) for Pfizer and BioNTechs Covid-19 vaccine to include adolescents aged 12 to 15 years.
The post US FDA approves emergency use of Pfizer-BioNTech Covid-19 vaccine in adolescents appeared first on ...

https://www.pharmaceutical-business-review.com/news/fda-pfizer-biontech-vaccine-adolescents/

#PharmaceuticalBusinessReview

Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China. Maralixibat is a minimally absorbed, orally
The post CANbridge signs license agreement with Mirum for maralixibat...

https://www.pharmaceutical-business-review.com/news/canbridge-mirum-maralixibat-greater-china/

#PharmaceuticalBusinessReview

Under the terms of the deal, CDR will pay 10.23 in cash per share in UDG. Headquartered in Dublin, UDG Healthcare provide healthcare advisory, communications, commercial, clinical and
The post CDR agrees to acquire UDG Healthcare for $3.7bn appeared first on Pharmaceutical Business review...

https://www.pharmaceutical-business-review.com/news/cdr-agrees-acquire-udg-healthcare/

#PharmaceuticalBusinessReview

The Russian Direct Investment Fund (RDIF) has announced that a single dose Covid-19 vaccine called Sputnik Light, obtained authorisation for use in the country. With recombinant human adenovirus
The post Russia approves single dose Covid-19 vaccine Sputnik Light appeared first on Pharmaceutical ...

https://www.pharmaceutical-business-review.com/news/russia-single-dose-covid-19-vaccine-sputnik-light/

#PharmaceuticalBusinessReview

The companies will leverage MiNA Therapeutics small activating RNA (saRNA) technology platform to develop the drug candidates. Using its saRNA platform, MiNA Therapeutics will research up to five
The post Lilly, MiNA Therapeutics partner to develop new drug candidates appeared first on ...

https://www.pharmaceutical-business-review.com/news/lilly-mina-therapeutics-drug-candidates/

#PharmaceuticalBusinessReview

World Health Organization (WHO) has granted emergency use listing (EUL) for Modernas Covid-19 vaccine to prevent the infection in people aged 18 years and above. The Covid-19 Vaccine
The post WHO grants emergency use listing for Modernas Covid-19 vaccine appeared first on ...

https://www.pharmaceutical-business-review.com/news/who-emergency-use-modernas-covid-19-vaccine/

#PharmaceuticalBusinessReview

Indias Defence Research and Development Organisation (DRDO) lab Institute of Nuclear Medicine and Allied Sciences (INMAS) developed the drug in alliance with Dr Reddys Laboratories (DRL). The drug
The post Indias DCGI allows use of oxygen dependence-lowering Covid-19 drug appeared first on ...

https://www.pharmaceutical-business-review.com/news/indias-dcgi-oxygen-dependence-lowering-covid-19-drug/

#PharmaceuticalBusinessReview

Besides acquiring the exclusive rights to commercialise PRG1801 inIndia, Dr. Reddys will be responsible for future development including clinical trials, inthe country. Pregene will be the sole supplier
The post Dr. Reddys signs license deal for anti-BCMA CAR-T PRG1801 in India ...

https://www.pharmaceutical-business-review.com/news/dr-reddys-license-anti-bcma-car-t-prg1801-india/

#PharmaceuticalBusinessReview